Wide Ranks

MDXG

MiMedx Group, Inc

9.43

Top Statistics
Market Cap 1 B Forward PE 30.42 Revenue Growth 2.90 %
Current Ratio 4.10 Trailing PE 16.54 Earnings Growth -9.70 %
Profit Margins 25.80 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 19.49 Enterprise / Revenue 3.84 Price To Sales Trailing12 Months 4.04
Profitability
Profit Margins 25.80 % Operating Margins 13.63 %
Balance Sheet
Total Cash 88 M Total Cash Per Share 0.6040 Total Debt 19 M
Total Debt To Equity 10.51 Current Ratio 4.10 Book Value Per Share 1.23
All Measures
Short Ratio 391.00 % Message Board Id finmb_35961030 Shares Short Prior Month 4 M
Return On Equity 0.6247 City Marietta Uuid f94c0942-c42c-3ae5-83ee-5792f556733a
Previous Close 9.23 First Trade Date Epoch Utc 1 B Book Value 1.23
Beta 1.94 Total Debt 19 M Volume 603090
Price To Book 7.65 Last Split Date 1 B Fifty Two Week Low 5.47
Total Cash Per Share 0.6040 Total Revenue 342 M Shares Short Previous Month Date 1 B
Target Median Price 12.00 Max Age 86400 Recommendation Mean 1.00
Sand P52 Week Change 0.3133 Operating Margins 13.63 % Target Mean Price 13.00
Net Income To Common 79 M Short Percent Of Float 0.0299 Implied Shares Outstanding 146 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 88 M Next Fiscal Year End 1 B
Revenue Per Share 2.45 Held Percent Insiders 0.0245 Ebitda Margins 19.69 %
Trailing PE 16.54 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 9.23 Target Low Price 11.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 6.79 Open 9.25 Free Cashflow 45 M
State GA Dividend Yield 0.00 % Return On Assets 0.1838
Time Zone Short Name EST Trailing Eps 0.5700 Day Low 9.25
Address1 1775 West Oak Commons Court, NE Shares Outstanding 146 M Price Hint 2
Target High Price 16.00 Website https://www.mimedx.com 52 Week Change 0.2136
Average Volume 746762 Earnings Quarterly Growth -5.10 % Forward Eps 0.3100
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 340.60 %
Last Split Factor 3235:10000 Regular Market Day High 9.64 Is_sp_500 False
Profit Margins 25.80 % Debt To Equity 10.51 Fifty Two Week High 9.64
Day High 9.64 Shares Short 3 M Regular Market Open 9.25
Industry Key biotechnology Earnings Growth -9.70 % Enterprise To Revenue 3.84
Revenue Growth 2.90 % Shares Percent Shares Out 0.0240 Operating Cashflow 57 M
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip 30062 Quote Type EQUITY
Industry Biotechnology Long Name MiMedx Group, Inc. Regular Market Day Low 9.25
Held Percent Institutions 0.6818 Current Price 9.43 Enterprise To Ebitda 19.49
Financial Currency USD Current Ratio 4.10 Gross Margins 83.37 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 108 M Two Hundred Day Average 7.04 Enterprise Value 1 B
Price To Sales Trailing12 Months 4.04 Forward PE 30.42 Regular Market Volume 603090
Ebitda 67 M Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.

Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications.

The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare.

The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States.

MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.